Latest from The Tisch Cancer Institute

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the role of bispecific agents in the treatment of patients with myeloma.
Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses the role of immunotherapy in the treatment of patients with myeloma.
Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.
Ajai Chari, MD, discusses novel treatment approaches for patients with heavily pretreated multiple myeloma.
Paula Klein, MD, discusses the research surrounding extended adjuvant therapy in early-stage hormone receptor-positive breast cancer.
Much needs to be done to improve interoperability of medical data systems. However, standards and new systems are developing at a rapid pace, affording advantages and efficiencies where, previously, enormous impediments stood in the way.
Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.
Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.
Publication Bottom Border
Border Publication
x